Lansforsakringar Fondforvaltning AB publ Has $45.31 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Lansforsakringar Fondforvaltning AB publ lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 404,400 shares of the biopharmaceutical company’s stock after selling 14,275 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Gilead Sciences were worth $45,313,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of GILD. Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Gilead Sciences by 15.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company’s stock valued at $1,130,117,000 after purchasing an additional 1,605,730 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Gilead Sciences by 30.1% during the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company’s stock valued at $801,655,000 after purchasing an additional 2,005,863 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at approximately $620,415,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the sale, the chief executive officer owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This trade represents a 1.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,339,230. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $113.92 on Thursday. The company’s fifty day moving average price is $112.83 and its two-hundred day moving average price is $109.35. The company has a market cap of $141.35 billion, a price-to-earnings ratio of 22.69, a PEG ratio of 0.70 and a beta of 0.33. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1-year low of $77.23 and a 1-year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GILD shares. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Finally, Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.